Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)

• Company Description    Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients. Number of Employees: 6,400

• Price / Volume Information    Yesterday's Closing Price: $83.84 Daily Weekly Monthly 20 Day Moving Average: 2,056,455 shares Shares Outstanding: 180.48 (millions) Market Capitalization: $15,131.05 (millions) Beta: 1.39 52 Week High: $85.82 52 Week Low: $29.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.51% 22.69% 12 Week 29.54% 20.25% Year To Date 69.34% 54.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5505 ENDEAVOR LANE - MADISON,WI 53719 USA ph: 608-284-5700 fax: 608-284-5701 meganjones@exactsciences.com http://www.exactsciences.com

• General Corporate Information    Officers Kevin T. Conroy - President; Chief Executive Officer and Chairman Jeffrey T. Elliott - Executive Vice President; Chief Financial Officer; Paul Clancy - Director D. Scott Coward - Director Freda Lewis-Hall - Director Peer Information Exact Sciences Corporation (CORR.) Exact Sciences Corporation (RSPI) Exact Sciences Corporation (CGXP) Exact Sciences Corporation (BGEN) Exact Sciences Corporation (GTBP) Exact Sciences Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30063P105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/01/23 Share - Related Items Shares Outstanding: 180.48 Most Recent Split Date: (:1) Beta: 1.39 Market Capitalization: $15,131.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.93 Price/Cash Flow: - Price / Sales: 6.88 EPS Growth vs. Year Ago Period: 59.62% vs. Previous Quarter: 41.67% Sales Growth vs. Year Ago Period: 23.82% vs. Previous Quarter: 8.94% ROE 03/31/23 - -16.64 12/31/22 - -19.76 09/30/22 - -22.10 ROA 03/31/23 - -8.18 12/31/22 - -9.80 09/30/22 - -11.06 Current Ratio 03/31/23 - 2.97 12/31/22 - 2.38 09/30/22 - 2.47 Quick Ratio 03/31/23 - 2.63 12/31/22 - 2.09 09/30/22 - 2.20 Operating Margin 03/31/23 - -23.49 12/31/22 - -29.92 09/30/22 - -35.73 Net Margin 03/31/23 - -23.49 12/31/22 - -29.92 09/30/22 - -35.73 Pre-Tax Margin 03/31/23 - -23.73 12/31/22 - -30.35 09/30/22 - -36.28 Book Value 03/31/23 - 16.94 12/31/22 - 17.13 09/30/22 - 17.57 Inventory Turnover 03/31/23 - 5.05 12/31/22 - 4.98 09/30/22 - 4.88 Debt-to-Equity 03/31/23 - 0.77 12/31/22 - 0.73 09/30/22 - 0.72 Debt-to-Capital 03/31/23 - 43.56 12/31/22 - 42.36 09/30/22 - 41.82

Powered by Zacks Investment Research ©